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FORMULASI DAN PENILAIAN AEROSOL EKSTRAK CHANNA STRIATUS 
DAN ASID FUSIDIK UNTUK RAWATAN LUKA DAN LUKA KEBAKARAN 
 
ABSTRAK 
 
Aerosol ialah sistem penyampaian drug yang baru untuk pembalutan dan 
perawatan luka. Aerosol mempunyai beberapa manfaat apabila dibandingkan dengan 
sistem penyampaian yang lain seperti plaster dan balutan untuk pembalutan luka dan 
krim atau gel untuk perawatan luka. Aerosol pada badan dapat mengurangkan 
kesakitan yang disebabkan kesan  gosokan mekanikal salap dan krim pada kulit. 
Aerosol mampu meliputi pelbagai saiz luka yang tidak mampu diliputi oleh filem 
kerana filem mempunyai saiz yang tetap. Channa striatus telah digunakan secara 
tradisional sejak dahulu untuk mempercepatkan penyembuhan luka. Ekstrak Channa 
striatus mengandungi asid amino dan asid lemak yang penting untuk proses 
penyembuhan. Asid fusidik ialah agen antimikrob untuk applikasi permukaan. 
Ekstrak Channa striatus dan campurannya dengan asid fusidik telah digunakan 
sebagai bahan aktif dalam kajian ini. Ekstrak Channa striatus mengandungi kira-kira 
3.61% protein. Sistem HPLC untuk kaedah analisis asid amino dan sistem GC untuk 
kaedah analisis asid lemak yang digunakan dalam kajian ini telah mencapai 
keperluan validasi. Sistem HPLC ini boleh dipercayai dan boleh dihasilkan semula. 
Ekstrak Channa striatus mengandungi asid amino yang boleh mempercepatkan 
proses penyembuhan luka. Ekstrak Channa striatus juga mengandungi omega-3 dan 
omega-6 yang amat penting dalam proses penyembuhan luka. Nisbah diantara 
omega-3 dan omega-6 asid lemak adalah 0.85. Omega-6 asid lemak diperlukan 
sebagai pencetus radang dalam fasa awal proses penyembuhan luka. HPMC adalah 
yang terbaik antara kesemua polimer yang telah diuji untuk menghasilkan kepekatan 
xxi 
 
untuk aerosol dan filem dengan kualiti yang dijangka. Glyserin digunakan sebagai 
agen pemplastik untuk formula E dan PEG 400 untuk formula G. Tokoferol 
digunakan sebagai antioksidan. Tin aerosol aluminium digunakan sebagai bekas. 
Berdasarkan kepada aspek keselamatan dan ekonomi, butana telah dipilih untuk 
digunakan sebagai agen pendorong untuk aerosol Channa striatus dan asid fusidik. 
Formula E2 (mengandungi ekstrak Channa striatus) dan G1(mengandungi ekstrak 
Channa striatus dan asid fusidik) tidak mempunyai sebarang potensi untuk 
menyebabkan iritasi pada kulit arnab, menunjukkan kedua-dua formula aerosol 
Channa striatus sesuai digunakan sebagai balutan luka. Perbandingan antara 
kumpulan-kumpulan yang dirawat dengan formula E2 dan G1 untuk kajian hirisan 
luka, menunjukkan formula E2 memberikan kekuatan regangan yang lebih baik 
berbanding formula G1 yang mengandungi asid fusidik sebagai bahan aktif. Ini 
mungkin disebabkan oleh kehadiran asid fusidik di dalam formula G1 yang merencat 
sintesis protein dan melambatkan proses penyembuhan. Peratus penutupan luka 
dalam kumpulan yang dirawat dengan formula E2 lebih tinggi berbanding kumpulan-
kumpulan lain (formula G1 dan blank). Dari hari ke-4 sehingga hari ke-12, rawatan 
menggunakan formula E2 menunjukkan peratus penutupan luka yang tinggi dan 
signifikan berbanding kumpulan-kumpulan lain. Kumpulan yang dirawat 
menggunakan formula E2 mencapai 82% penutupan luka pada hari ke-10 dan 98% 
penutupan luka pada hari ke-15, manakala dua kumpulan yang lain mencapai 82% 
dan 98% penutupan masing-masing hanya pada hari ke-12 dan hari ke-18. Ini 
menunjukkan bahawa formula aerosol yang mengandungi ekstrak Channa striatus 
boleh mempercepatkan proses penyembuhan luka berbanding formula aerosol G1 
dan blank. 
 
 
xxii 
 
FORMULATION AND EVALUATION OF CHANNA STRIATUS EXTRACT 
AND FUSIDIC ACID AEROSOL FOR TREATMENT OF WOUNDS AND 
BURN  
 
ABSTRACT 
 
Aerosol is a new drug delivery system for wound dressing and wound treatment. 
Aerosol has several benefits when compared with other delivery systems such as 
plasters or bandages for wound dressing and cream or gel for wound treatment. 
When applied to the body aerosol reduces pain that may result from the mechanical 
rubbing of gel and creams onto the skin. Aerosol could cover any size of wound 
which could not be covered by films due to films have a fixed size. Channa striatus 
has been used since a long time ago traditionally to accelerate the wound healing. 
Channa striatus extract contained amino acids and fatty acids which important for 
healing process. Fusidic acid is an antimicrobial for topical application. Channa 
striatus extract and in combination with fusidic acid have been used as active 
ingredients in this study. Channa striatus extract contained about 3.61% protein. 
HPLC systems for amino acids analysis and GC systems for fatty acids analysis 
method used in this study met the requirements of validation. These HPLC systems 
are reliable and reproducible. Channa striatus extract contained amino acids that 
could promote the wound healing process.  Channa striatus extract also contained 
omega-3 and omega-6 that are very important in wound healing process. Ratio 
between omega-3 and omega-6 fatty acids was 0.85. Omega-6 fatty acid is needed as 
inflammatory inducer in the early phase of wound healing process. HPMC is the best 
among polymers tested to produce concentrate for aerosols and films with the 
expected qualities. Glycerine has been used as plasticizer for formula E and PEG 400 
xxiii 
 
for formula G. Tocopherol was used as antioxidant. Aerosol aluminium can was used 
as container. Based on safety and economic aspect, butane was chosen to be used as 
the propellant for Channa striatus and fusidic acid aerosols. Formulas E2 (containing 
Channa striatus extract) and G1 (containing Channa striatus extract and fusidic acid) 
did not have any potential irritant ability to the rabbits skin, indicating that both of 
Channa striatus aerosol formulas can be applied as a wound dressing without any 
undesirable effect. Comparison between the groups treated with formula E2 and G1 
for incision wound study, showed that formula E2 gave a better tensile strength than 
formula G1 which contained fusidic acid as additional active ingredient. This might 
be due to the presence of fusidic acid in formula G1 which inhibited the protein 
synthesis and delayed the healing process. Percentage of wound closure of the group 
which treated with formula E2 is higher than other groups (formula G1 and blank). 
From day 4 until day 12, formula E2 treatment significantly showed a higher 
percentage of wound closure compared to the other groups. Group which treated with 
formula E2 reached 82% wound closure on day-10 and 98% wound closure on day-
15, whereas other two groups reached 82% and 98% closure only on day-12 and on 
day-18 respectively. It means that the aerosol formula containing Channa striatus 
extract could accelerate the wound healing process as compared to aerosol formula 
G1 and blank.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 AEROSOL 
Aerosol dosage form for oral and topical application was developed for use in 
the mid-1950s. Since that time it has found widespread acceptance because of its 
ease of use and therapeutic efficacy. The first textbook devoted exclusively to the 
subject of aerosol science and technology appeared in 1958 and was authored by 
Herzka and Pickthall (Sciarra, 1974). 
Pharmaceutical aerosols are dosage forms containing therapeutically active 
ingredients intended for topical administration, introduction into body cavities or by 
inhalation via the respiratory tract (Sciarra and Cutie, 1990b). The dosage form is 
packaged in a metal or glass container and sealed with either a metered or 
continuous-spray valve. The aerosol product itself consists of four components: 
concentrate (containing the active ingredient(s), propellant(s), container and valve-
actuator (Sciarra, 1976). The propellant provides the internal pressure that forces the 
product out of the container when the valve is opened and delivers the product in its 
desired form. For metered dose inhalers (MDIs) the product is delivered as a finely 
dispersed mist (particles less than 8 µm in diameter). Topical aerosol delivers its 
content as a spray, foam, or semisolid (Sciarra, 1996; Sciarra and Stoller, 1974). 
Topical pharmaceutical aerosols have been accepted by both patients and 
physicians because of their aesthetic properties, ease of application, maintainability 
of sterility (if the package is sterile), tamperproof system, prevention of 
contamination of the unused contents, and increased stability. Topical aerosols have 
been dispensed as sprays, foams, and semisolids. When applied to the body they 
avoid or reduce pain that normally may result from the mechanical rubbing of 
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ointments and creams onto the skin. Through use of a metered dose valve, an 
accurate amount of medication can be dispensed each time the valve is actuated. 
Topical products that have been formulated as aerosol include first-aid products 
containing local anaesthetics and antiseptics, adhesive tape removers and bandage 
adherents, products used in athletic and sports, burn remedies, foot preparations, 
germicidal and disinfectant products, spray-on bandages, protective, topical 
dermatologic, including antibiotics and steroids, veterinary products, body liniments 
and rubs, products for vaginal and rectal applications which include contraceptive 
foams and rectal foams, edible foams and saline solutions to cleanse contact lenses 
(Sciarra, 1996; Sciarra and Stoller, 1974). 
 
1.1.1 Concentrate 
The concentrate can be of the solution, dispersion, emulsion, or semisolid 
type. The concentrate is made up of active ingredient(s) and may include solvent(s) 
and dispersing agent. Depending on the type of product, various inert ingredient(s) 
are used as additive(s) to prepare solutions, suspensions, and emulsions (Sciarra, 
1996; Sciarra and Stoller, 1974). 
(a) Solution Systems 
This type of aerosol system consists of two distinct phases: liquid and 
vapour. The solvent is used to dissolve the active ingredient and/or to retard the 
evaporation of the propellant. Solution aerosols are relatively easy to formulate, 
provided that the ingredients are soluble in the propellant. However, the 
liquefied gas propellants are nonpolar in nature and in most cases are poor 
solvents for some of the commonly used medicinal ingredients. Through use of a 
solvent that is miscible with the propellant, one can achieve varying degrees of 
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solubility. Ethyl alcohol has found widespread use for this purpose. Other 
solvents use in pharmaceuticals may also be used with topical aerosols (Sciarra, 
1996). 
When the valve of a solution aerosol is depressed, a mixture of active 
ingredients, solvents, and propellants which has a very high vapour pressure is 
forced and emitted into the atmosphere. As the liquid propellant encounters the 
surrounding atmospheric (very much lower vapour pressure) air, it tends to 
vaporize and, in so doing, breaks up the active ingredients and solvents into fine 
particles. Depending on their size, the particles remain suspended in air for 
relatively long period of time. The particles sizes of aerosol can vary from as 
small as 5 to 10 µm or less to as large as 50 to 100 µm (Sciarra and Stoller, 
1974). The size of aerosol droplets produced will depend on the nature of the 
propellant, the amount of propellant, the nature of the product concentrate, and 
the valve design. Metered-dose inhalers require particles of less than 8 µm 
whereas nasal aqueous aerosols generally have particles in the range of 50 to 75 
µm. Topical aerosols have a particle size of about 100 µm (Sciarra, 1996). 
 
Table 1.1: Prototype formulation for topical aerosol solutions (Sciarra and Cutie, 
1990b)  
 
Active ingredient(s) Dissolved in system 
Solvents 
 
Ethyl and isopropyl alcohol 
Glycols 
Isopropyl esters 
Surfactants 
Antioxidants Ascorbic acid 
Preservative Methyl and propyl parabens 
Propellant(s) Isobutane 
Propane/butane 
Propane/isobutene 
Propellant 22 
Propellant 152/142 
Propellant 22/142 
Dimethyl ether 
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(b) Suspension systems 
For substances that are insoluble in the propellant or the mixture of 
propellant and solvent, or in cases where a cosolvent is not desirable, the active 
ingredients can be suspended in the propellant vehicle. When the valve is 
depressed, the suspension is emitted, followed by rapid vaporization of the 
propellant, leaving behind the finely dispersed active ingredients. This system 
has been used successfully to dispense anti-asthmatic aerosol as well as topical 
aerosol containing antibiotics. However, the formulation of this type of aerosol 
is not without difficulty. Problems involving caking, agglomeration, particle size 
growth and clogging of the valve arise (Sciarra and Stoller, 1974). Salt of the 
active ingredient having very low solubility or not soluble in the propellant and 
solvents should be selected. It is the slight solubility of the active ingredients in 
the propellants and solvents that contributes to particle size growth. This 
phenomenon, known as Ostwald Ripening occurs because the small particles 
have higher equilibrium solubility than larger particle of the same substance. 
These small particles will gradually dissolve and deposited onto the surface of 
the larger particles, resulting in an increase in the particle size of the originally 
micronized active drug substances. By adjusting the density of both the 
propellant and/or the insoluble material so that they are approximately equal, the 
rate of sedimentation can be reduced substantially. This can be accomplished by 
using a mixture of different propellants of varying densities as well as by 
addition of an inert powder to the active ingredients. Final consideration should 
be given to the use of a surfactant or dispersing agent. Sorbitan oleate, lecithin, 
oleic acid, and oleyl alcohol have been used in oral and metered-dose inhalers; 
isopropyl myristate has been used primarily in topical aerosols. Although it may 
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be easier to formulate a solution system compared to a suspension system, the 
latter is generally preferred because one can obtain closer control over the 
particle size distribution of droplets dispersed in the suspension aerosol. 
Suspensions generally show greater stability of the active ingredient as 
compared with solution (Sciarra, 1996; Sciarra and Stoller, 1974). 
 
Table 1.2: Prototype formulation for topical aerosol suspensions (Sciarra and 
Cutie, 1990b) 
 
Active ingredient(s) Pass through a 325 mesh screen 
Dispersing agents 
 
Isopropyl myristate 
Mineral oil 
Sorbitan esters 
Polysorbates 
Glycerol ethers and derivatives 
Propellant(s) 12/11; 12/114 (only if exempted) 
Hydrocarbons 
142, 152, 22 
Dimethyl ether 
 
(c) Emulsion systems 
Water and hydrocarbon or fluorinated hydrocarbon propellants are not 
miscible. In order to formulate a suitable aerosol using these materials, various 
techniques can be used. An emulsion aerosol consists of active ingredient(s), 
aqueous or non aqueous vehicle, surfactant and propellant. Depending on the 
choice of ingredients, the product can be emitted as stable or quick-breaking 
foam or as a spray (Sciarra, 1996; Sciarra and Stoller, 1974). 
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Table 1.3: Prototype formulation for topical aerosol emulsions/foam (Sciarra 
and Cutie, 1990b) 
 
Active ingredient(s) Solubilised in fatty acid, vegetable oil, glycol 
Emulsifying agents 
 
Fatty acid soaps (triethanolamine stearate) 
Polyoxyethylene Sorbitan esters 
Emulsifiable waxes 
Surfactants 
Other modifiers 
 
Emollients 
Lubricants 
Presevatives 
Perfumes 
Propellant(s) 12/114 (only if exempted) 
Hydrocarbons 
22/152 
22/142 
152/142 
Dimethyl ether 
 
(i) Foam system 
The propellant used in an emulsion is an important part of this 
system and determines the type of foam produced. The propellant is generally 
considered part of the immiscible phase and as such can be in the internal or 
external phase. When the propellant is included in the internal phase, typical 
stable or quick-breaking foam is emitted. When the propellant is in the 
external phase, the product is dispensed as a spray (Sciarra, 1996; Sciarra and 
Stoller, 1974).  
(ii) Stabilized foams 
In an emulsion system where the propellant is in the internal phase 
(generally part of the oil phase of the emulsion), water makes up the external 
or dispersing phase. The propellant is generally used to the extent of about 
7% to 10% of the total weight. When a hydrocarbon propellant is used (such 
as isobutane/propane blend) as little as 3% to 4% is sufficient to produce 
suitable foam. These propellants are emulsified in the aqueous or nonaqueous 
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emulsion. Some of the propellant will vaporize in the container and be present 
in the head space to produce the necessary vapour pressure. The pressure 
should be approximately 40 psig, depending on the propellant used. When the 
valve is depressed, the pressure provided by the vaporised propellant forces 
the emulsion up the dip tube and out the valve. The low atmospheric pressure 
cause the propellant trapped in the emulsion droplets to expand and vaporises 
to form stable foam, e.g. shaving foams (Sciarra, 1996; Sciarra and Stoller, 
1974). 
(iii) Quick-breaking foams 
These foams consist of ethyl alcohol, water, and a surfactant that is 
soluble in either alcohol or water but not in both. Other miscible solvents can 
be used in place of alcohol and water. The surfactant can be non-ionic, 
anionic, or cationic. The product is dispensed as foam but quickly collapse, so 
that there is no further injury by mechanical dispersion of the product. 
Steroid, burn, and other topical preparations can be applied in this 
manner. One advantage of a foam system over an aerosol system is the fact 
that the area with which the product comes into contact is limited or can be 
controlled. Preparations containing irritating ingredients may also be 
dispensed in this manner. The incidence of airborne particles can be 
substantially reduced, thereby lowering the incidence of toxicity of the 
sprayed products which may cause irritation on release and may be inhaled 
(Sciarra, 1996; Sciarra and Stoller, 1974). 
(iv) Spray emulsion 
The base for this product is a water-in-oil emulsion. A fairly large 
amount of propellant (about 25% to 30%) is miscible with the outer oil phase 
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so that the propellant remains in the external phase of the final emulsion. 
When this system is dispensed, the propellant vaporizes, leaving behind 
droplets of water-in-oil emulsion with no foaming. Because the propellant 
and concentrate phase tend to separate on standing, products formulated using 
this system must be shaken before use. A hydrocarbon propellant or a mixed 
hydrocarbon/fluorocarbon propellant is preferred for this system, because the 
specific gravity of the propellant is less than 1 and the propellant will float on 
the aqueous layer. In addition, such systems use a vapour tap valve, which 
tends to produce finely dispersed particles (Sciarra, 1996; Sciarra and Stoller, 
1974). 
 
1.1.2 Propellants 
The propellant can be either a liquefied or a compressed gas. The propellant 
is responsible for developing the proper pressure within the container and for 
expulsion of the product when the valve is opened. It also is responsible (together 
with the valve) for dispensing the product as a spray, foam, or semisolid. Various 
types of propellants are utilized. The fluorinated hydrocarbons, such as 
trichloromonofluoromethane (propellant 11), dichlorodifluoromethane (propellant 
12), and dichlorotetrafluoro-ethane (propellant 114) found widespread use in most 
aerosol for oral, nasal, and inhalation use. Topical pharmaceutical aerosols utilize 
hydrocarbons (propane, butane, and isobutene) a limited number of 
hydrofluorocarbons and hydrochlorofluorocarbons (142b, 152a, 22), and compressed 
gases such as nitrogen and carbon dioxide (Sciarra, 1996; Sanders, 1979). 
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(a) Chlorofluorocarbons (CFCs) 
The use of chlorinated fluorocarbons for aerosols and other commercial 
uses has been seriously curtailed and, in certain cases, banned. These compounds 
have been implicated in causing a depletion of the ozone layer and partially 
responsible for the “greenhouse” effect (increase in earth’s temperature, rising 
sea levels, and altered rainfall patterns) (Sciarra, 1996). 
Prior to 1978, fluorinated hydrocarbons were used almost exclusively as 
the propellants for all types of pharmaceutical aerosols. Their chemical inertness, 
lack of toxicity, lack of flammability and explosiveness and their safe record of 
use made them ideal candidates for use. The publication of the “ozone depletion 
theory” in the mid-1970s, however, and the alleged implication of the 
fluorocarbons in depleting the ozone levels in the atmosphere, led to the phasing 
out and ban of the use of fluorocarbon propellants in aerosols (with few 
exceptions) in 1978. This ban, promulgated by the Environmental Protection 
Agency (EPA), Food and Drug Administration (FDA) and the Consumer 
Products Safety Commission, became fully effective in April 1979, when 
manufacturers could no longer ship aerosol products containing fluorocarbons 
unless the product carried a specific federal exemption. While some propellant 
manufacturers indicated that there were other suitable replacements for 
propellants 11, 12, and 114, the only ones that have survived the necessary 
toxicity tests (long- and short-range) are fluorocarbons 152a, 142b and 22 which 
may be of limited value. The other alternatives include hydrocarbons, 
compressed gases, and mechanical devices and pumps. Of these alternatives, 
hydrocarbons were restricted to use with foams and water-based aerosols while 
compressed gases were of limited value in aqueous products where the propellant 
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and water were not miscible. When compressed gases overcame the immiscibility 
of the components, other problems such as loss of propellant and to a lesser 
degree the change in the dispersion of the spray became apparent. Since 
compressed gas systems do not have chilling effect, they are applicable to topical 
preparations. With the development of newer valve technology (the vapour tap 
and the Aquasol valve), it was found that hydrocarbon propellants, such as 
butane, propane, isobutene and their mixtures could be safely used not only with 
aqueous products but with solvent-based aerosol as well. At present, 
hydrocarbons can be used for all types of topical aerosols (Sciarra and Cutie, 
1986). 
All MDIs marketed prior to 1995 contained CFCs as a propellant. These 
are also implicated in the depletion of stratospheric ozone. Except for some 
specific exemptions; their production has been banned since 1996 under the 
terms of the Montreal Protocol (UNEP, 2000). Hydrofluoroalkanes have been 
identified as suitable alternatives for MDI propellants but their physico-chemical 
properties differ significantly from CFCs and an extensive redevelopment and 
testing programme has been required to demonstrate the safety, quality and 
efficacy of hydrofluoroalkanes (HFAs) containing MDIs. HFAs contribute to 
global warming but the benefit to human health through continued MDI 
availability currently outweighs the environmental concern. Several HFA-MDIs 
have reached the market and the transition to replace existing CFC-MDIs is now 
underway (Smyth et al., 2005; McDonald and Martin, 2000). 
(b) Hydrochlorofluorocarbons and hydrofluorocarbons 
Topical pharmaceutical products must be formulated using a propellant 
other than the chlorofluorocarbons. For this purpose, a series of 
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hydrochlorofluorocarbons and hydrofluorocarbons are available. These 
propellants do not present a hazard to the environment and can be used 
successfully to formulate topical pharmaceuticals. Table 1.4 illustrates these 
propellants along with some of their more useful physicochemical properties. As 
can be seen from Table 1.4, these propellants have suitable vapour pressures 
making them useful for a variety of different products. Propellant 152a and 142b 
may be blended to yield a vapour pressure within the useful range of from 35 to 
50 psig. They may also be blended with propellant 22 to give the desired 
nonflammability to the final mixture as well as to obtain a higher vapour pressure 
(Sciarra, 1996). 
 
Table 1.4: Propellants useful for topical pharmaceutical aerosol 
Designation Propellant 22 
Propellant 
142b 
Propellant 
152a 
Formula 
Molecular weight 
Boiling Point, 
0
F (
0
C) 
Vapour pressure (psig), 70 
0
F 
Vapour pressure (psig), 130 
0
F 
Density (g/mL), 70 
0
F 
Solubility in water (wt.%), 70 
0
F 
Kauri-butanol value 
Flammability limits in air (vol. 
%) 
Flash point, 
0
F 
CHClF2 
86.5 
-41.4(-40.8) 
121 
297 
1.21 
3.0 
25 
 
Nonflammable 
- 
CH3CClF2 
100.5 
14.4(-9.44) 
29 
97 
1.12 
0.5 
20 
 
6.3-14.8 
-  
CH3CHF2 
66.1 
-11.2(-23.0) 
62 
176 
0.91 
1.7 
11 
 
3.9-16.9 
- 
 
(c) Hydrocarbons 
The hydrocarbon propellants; butane, propane, and isobutene have 
replaced the chlorofluorohydrocarbons as the propellant for most consumer 
aerosol products (other than MDIs). They have also been used for topical 
pharmaceuticals. They are ideal for use with foams because they are nontoxic, 
nonreactive, and relatively inexpensive. They yield satisfactory foam and are 
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environmentally acceptable. The chief drawback to their use is their 
flammability. However, this is of greater concern to the manufacturer than to the 
consumer. The advantage of hydrocarbons is their greater range of solubility and 
lower cost compared to fluorinated hydrocarbons. Their density of less than 1 and 
their immiscibility with water, make them useful in formulation of three-phase 
(two-layer) aerosols. Being lighter than water, the hydrocarbon remains on top of 
the aqueous layer and serves to push the contents out of the container. They are 
not subject to hydrolysis, making them useful with water-based aerosols (Sciarra 
and Cutie, 1990a).  
 
Table 1.5: Selected properties of hydrocarbons and dimethyl ether 
Designation Propane Isobutane n-Butane DME 
Formula 
Molecular weight 
Boiling Point, 
0
F (
0
C) 
Vapour pressure (psig), 
70 
0
F 
Vapour pressure (psig), 
130 
0
F 
Density (g/mL), 70 
0
F 
Solubility in water 
(wt.%), 70 
0
F 
Kauri-butanol value 
Flammability limits in 
air (vol.%) 
Flash point, 
0
F 
C3H8 
44.1 
-43.7(-42.0) 
109 
 
257 
 
0.50 
0.01 
 
15 
2.2-9.5 
 
-156 
i-C4H10 
58.1 
10.9(-11.7) 
31 
 
97 
 
0.56 
0.01 
 
17 
1.8-8.4 
 
-117 
n-C4H10 
58.1 
31.1(-0.56) 
17 
 
67 
 
0.58 
0.01 
 
20 
1.8-8.5 
 
-101 
CH3OCH3 
46.07 
-12.7 
63 
 
174 
 
0.66 
34 
 
60 
3.4-18 
 
-42 
 
As can be seen in Table 1.5, they all have a density of about 0.5 to 0.6 
g/mL and therefore less is required as compared to a fluorocarbon (generally 1.2 
to 1.4 g/mL). They can also be blended with each other and with 
hydrochlorofluorocarbons and hydrochlorocarbons so as to obtain different 
vapour pressures. Recently, dimethyl ether has been used to formulate aerosols. 
As can be seen in Table 1.5, its main advantage over all other materials used in 
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aerosol formulations is its rather high miscibility with water (about 34%). This 
allows the formulator greater flexibility in developing different types of aerosol 
systems (Sciarra, 1996). 
(d) Compressed gases 
The compressed gases nitrogen, nitrous oxide, and carbon dioxide are 
limited in use. They are used in those cases where large quantity of water is 
present and the product must be dispensed as a spray. Such is the case with 
contact lens cleaners. Nitrogen is used because its inertness and its lack of 
solubility and miscibility with water. It is used to push the contents out of the 
container and to dispense a fine stream of solution that can be directed to the 
contact lens. Nitrous oxide and carbon dioxide are used with products where 
solubility of the gas in the product is desirable. Their main use at the present time 
is with foams. Table 1.6 indicates some of the other properties of these gases. 
Unlike liquefied gases, there is a drop in pressure as the contents of a product 
using compressed gas as propellant are dispensed (Sciarra, 1996). Since 
compressed gases are utilized in the gaseous state and not in the liquid state 
which may act as depot for the propelling gas, a higher initial pressure is 
required, as well as a relatively larger head space as in liquefied-gas aerosols. 
While the pressure of a liquefied-gas aerosol remains constant during use because 
the pressure is not influenced by the head space but by the mole ratio of the gas 
which remain constant during use and the gas is constantly replaced by the 
evaporating propellant liquid. A drop in pressure is noted during use of a 
compressed-gas aerosol because the gas pressure drop as the volume of head 
space increase (Sciarra and Cutie, 1990a). 
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Table 1.6: Properties of the compressed gases 
Designation 
Carbon 
dioxide 
Nitrous 
oxide 
Nitrogen 
Formula 
Molecular weight 
Solubility in water (%w/w, 70 
0
F, 
100 psig) 
Solubility in isobutene 
Solubility in ethyl alcohol 
Solubility in Propellant 11 
CO2 
44.0 
 
1.5 
5.3 
5.6 
3.5 
N2O 
44.0 
 
0.7 
7.3 
5.7 
4.9  
N2 
28.0 
 
- 
- 
- 
- 
 
For safety reasons, the package should not be filled full to the top with liquid 
or concentrate. There must always be sufficient space for the propellant gas to 
occupy. The actual amount of liquid or concentrate that can be filled into an aerosol 
container is controlled by legislation, and there has to be a greater head space when 
using compressed gas propellants. 
 
1.1.3 Containers 
The concept of an aerosol originated as early as 1790, when self-pressurized 
carbonated beverages were introduced in France. In 1837, Perpigna invented a soda 
siphon incorporating a valve. Metal aerosol cans on the other hand were being 
introduced and tested as early as 1862. They were constructed from heavy steel and 
were too bulky to be commercially successful.  In 1899, inventors Helbling and 
Pertsch patented aerosols pressurized by methyl and ethyl chloride as propellants. 
Department of Agriculture researchers, Lyle Goodhue and William Sullivan, 
developed a small aerosol can pressurized by a liquefied gas (a fluorocarbon) in 1943 
(Bellis, 1997; Stoller, 1974).  
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In 1949, Robert H. Abplanalp’s invention of a crimp on valve enabled liquids 
to be sprayed from a can under the pressure of an inert gas. In 1953, Robert H. 
Abplanalp patented his crimp-on valve "for dispensing gases under pressure." In the 
mid-1970s, concern over the use of fluorocarbons adversely affecting the ozone layer 
drove Abplanalp back into the lab for a solution. Robert H. Abplanalp invented both 
the first clog-free valve for aerosol cans and the "Aquasol" or pump aerosol, which 
used water-soluble hydrocarbons as the propellant source (Bellis, 1997).  
(a) Glass 
Glass bottle are not recommended for suspension aerosol because of the 
visibility of the suspended particles may present an aesthetic problem for the 
patient. Glass, being inert, has always been preferred for use with all types of 
pharmaceuticals, but with the advent and introduction of many newer materials, 
glass has been replaced by aluminium containers for most aerosols.  
Glass does have several advantages (Chapman, 2004): 
(i)  It is inert to most medicinal products 
(ii)  It is impervious to air and moisture 
(iii) It allows easy inspection of the container contents 
(iv) It can be coloured to protect contents from harmful wavelengths of light 
(v)  It is easy to clean and sterilized by heat 
(vi) It is available in variously shaped containers 
 
The disadvantages of glass (Chapman, 2004) are: 
(i) It is fragile: glass fragments can be released into the product during transport 
or contaminants can penetrate the product by way of cracks in the container. 
(ii)  Certain types of glass release alkali into the container contents. 
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(iii) It is expensive when compared to the price of plastic. 
(iv) It is heavy resulting in increased transport costs. 
The chemical stability of glass for pharmaceutical use is governed by the 
resistance of the release of soluble minerals into water contacting the glass. 
This is known as the hydrolytic resistance. Details of four types of glass are 
given in the BP (2007) and Ambrosio (2002). 
 
(b) Aluminium 
Aluminium is extremely lightweight and also is essentially inert. 
Aluminium can be used without an internal organic coating for certain aerosol 
formulations (especially those that contain only active ingredient and propellant) 
but many are available with an internal coating made from an epon- or expoxy-
type resin (Sciarra, 1996; Sciarra and Cutie, 1986). 
 
(c) Tin-Plated steel 
These containers are used for most nonpharmaceutical aerosol and are the 
least expensive and most versatile of all containers (Sciarra, 1996; Sciarra and 
Cutie, 1986). 
 
(d) Other container 
There are many additional container systems available that allow for 
special dispensing of some product. The viscosity of the product, incompatibility 
of the product concentrate and propellant and desired dispensing characteristics 
of the finished product represent a few of the reasons why the typical aerosol 
systems may be unsuitable (Sciarra, 1996; Sciarra and Cutie, 1986). 
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1.1.4 Valves 
A Valve is an important component of all aerosols and is responsible together 
with the propellant for the delivery of the product in the desired form whether as a 
spray, foam, semisolid, or as a fine mist having particles below 8 µm that suitable for 
inhalation (Sciarra, 1996; Sciarra and Cutie, 1986). 
(a) Metered Valves 
Metered valves, fitted with a 20 mm ferrule, are used with glass bottles 
and aluminium canisters for all MDIs (Sciarra, 1996). 
(b) Continuous-Spray Valves 
These valves are used primarily with topical pharmaceuticals. Table 1.7 
indicates some of the commonly used materials for each of the subcomponents. 
These materials must be tested with the specific formulation in order to 
determine its compatibility with the formulation. Leakage and/or absorption (or 
adsorption) of the active ingredient are sometimes noted with these valves and 
generally can be overcome through proper selection of the material of 
construction (Sciarra, 1996; Sciarra and Cutie, 1986). 
 
Table 1.7: Materials used in valve construction 
Subcomponent Material 
Actuator (button, spout) 
Mounting cup 
Mounting cup gasket 
Stem 
Stem gasket 
Spring 
Body 
Dip tube 
Polypropylene, polyethylene 
Tinplate, aluminium 
Flowed-in or polyethylene sleeve 
Nylon, delrin, acetal 
Buna N, neoprene, butyl 
Stainless steel-passivated, stainless steel 
Nylon, delrin, acetal 
Polyethylene, polypropylene 
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Depending on the design of the actuator or spout, the product can be 
dispensed as a spray, foam, or semisolid (Sciarra, 1996; Sciarra and Cutie, 1986).  
 
1.2 AEROSOL FORMULATION, MANUFACTURING PROCEDURE AND 
QUALITY CONTROL 
 
An aerosol formulation consists of two essential components: product 
concentrate and propellant. The product concentrate consists of active ingredients, or 
a mixture of active ingredients and other necessary agents such as solvents, 
antioxidants and surfactants. The propellant may be a single propellant or a blend of 
various propellants and is selected to give the desired vapour pressure, compatibility 
and dispensing characteristics (Sciarra, 1996; Sciarra and Cutie, 1986). 
Both manufacturing procedures and packaging must be considered 
simultaneously, as part of the manufacturing operation takes place during the 
packaging of the product. The concentrate, which contains the active ingredients, 
solvents and cosolvents, other inert ingredients and may even contain a small portion 
of the propellant are compounded separately and then mixed with the remainder of 
the propellant. Two methods are available for use that includes a cold-fill and a 
pressure-fill method. Present-day technology and the availability of good equipment 
give preference to the pressure method over the cold-fill method. Less propellant 
may escapes into the atmosphere from the pressure fill method thus is more 
environmentally friendly (Sciarra, 1996). 
A quality control system for aerosol is no different from the system used for 
nonaerosol pharmaceuticals except that several in-process tests are necessary in order 
to ensure that the concentrate has been properly prepared. In most cases this will 
include an assay to determine the level of active ingredient present. Other tests are 
dependent on the nature of the product. Weights of both the concentrate and the 
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propellant must be checked routinely throughout the manufacturing process. Any 
errors and variation will affect the strength of active ingredient present in the final 
product and will result in product’s rejection. Other essential tests that must be 
carried out on topical aerosol include: pressure, weight loss, delivery-amount/second, 
specific gravity, density, viscosity, interaction of product with valve, interaction of 
product with container, aerosol valve discharge rate, spray pattern, net contents, 
particle size, leakage and others depending on nature of product (Sciarra, 1996; 
Sciarra and Cutie, 1986). 
 Aerosol to be formulated in this study is a drug delivery system which 
delivers spray-bandage. Aerosol sprayed on the wound surface would release the 
active ingredient and additives onto the wound and form a thin layer of bandage that 
would cover and protect the wound. The aerosol to be formulated would contain the 
suitable type and amount of film-forming polymer and plasticizer which could 
produce the proper film for covering the wound and function as dressing.  
Films prepared from pure polymers frequently are brittle and crack on drying. 
To correct this deficiency, the polymer can be chemically modified or other 
ingredients can be added to make the film more pliable. As a general rule, the film 
will become more flexible and more resistant to mechanical stress when a plasticizer 
is added to a film composition. There is an optimal concentration of plasticizer to be 
used for any film composition (Seitz, 1988). 
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1.3 CHANNA STRIATUS 
 
Figure 1.1: Channa striatus fish 
 
Taxonomy of Channa striatus fish are (Zipcodezoo, 2010): 
Domain  : Eukaryota  
Kingdom  : Animalia  
Subkingdom  : Bilateria  
Branch   : Deuterostomia  
Infrakingdom  : Chordonia  
Phylum  : Chordata  
Subphylum  : Vetebrata  
Infraphylum  : Gnathostomata  
Superclass  : Osteichthyes  
Class   : Actinoterygii  
Subclass  : Actinopterygii  
Infraclass  : Actinopteri   
Cohort   : Clupeocephala  
Superorder  : Acanthopterygii  
Order   : Perciformes  
Suborder  : Channoidei 
Family   : Channidae  
Genus   : Channa  
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Specific name  : striata  
Scientific name : Channa striata  
There are 52 species in Channa genus i.e. C. africanus, C. amphibeus, C. 
arga, C. argus (Northern Snakehead), C. argus argus (Snakehead), C. argus 
warpachowskii (Northern Snakehead), C. asiatica (Small Snakehead), C. 
aurantimaculata, C. bankanensis, C. baramensis, C. barca (Barca Snakehead), C. 
bistriata, C. bleheri, C. burmanica, C. cyanospilos, C. diplogramma, C. elliptica, C. 
fasciata, C. formosa, C. gachua, C. grandinosa, C. harcourtbutleri (Burmese 
Snakehead), C. leucopunctatus, C. lucius, C. maculata (Blotched Snakehead), C. 
maculatus, C. marulioides, C. marulius (Bullseye Snakehead), C. marulius ara, C. 
marulius marulius (Bullseye Snakehead), C. melanoptera, C. melanosoma, C. 
melasoma (Black Snake Mackerel), C. microlepis, C. micropeltes (Indonesian 
Snakehead), C. micropeltis (Indonesian Snakehead), C. nox, C. obscura, C. obscurus, 
C. ocellata, C. orientalis (Smooth-Breasted Snakefish), C. panaw, C. 
pleurophthalma, C. punctata (Spotted Snakehead), C. punctatus, C. sinensis, C. spp, 
C. stewartii (Assamese Snakehead), C. striata (Striped Snake Head Murrel), C. 
striatus, C. theophrasti, and C. argus subsp. warpachowskii (Zipcodezoo, 2010) 
Unambiguous Synonyms for Channa striata are: 
1. Channa striatus Bloch, 1793 
2. Ophicephalus planiceps Cuvier, 1831 
3. Ophicephalus striatus Bloch, 1793 
4. Ophiocephalus chena Hamilton, 1822 
5. Ophiocephalus philippinus Peters, 1869 
6. Ophiocephalus planiceps Cuvier, 1831 
7. Ophiocephalus striatus Bloch, 1793 
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8. Ophiocephalus vagus Peters, 1869 
9. Ophiocephalus wrahl Lacepède, 1801 
Original description of Channa striatus is Ophicephalus striatus Bloch, 1793 
in Naturgeschichte der Auslandischen Fische, 7:I-xiv + 1-144, pls. 325-360. Channa 
striatus fish has size up to 91.4 cm and can attain a length of 30-36 cm in 1 year. 
Channa striatus has habitat in freshwater ponds and streams, usually in stagnant 
muddy waters; primarily found on plains in India. Nevertheless, in Malaysia this 
species is reported to exist in rivers, lakes, swamps, paddy fields, mining pools, and 
roadside ditches. Channa striatus is an obligate air breather; spend up to 15 percent 
of the time in surfacing and related activities. This species is carnivorous, feeding on 
worms, prawns, frogs and fishes especially of other species (Courtenay et al., 2007). 
In Malaysia, it has always be a strong belief that Channa striatus enhance 
wound healing and a very powerful tool for recovery of health and injury of mothers 
after giving birth. Since 1931 there has been in Malaysian literature about wound 
treatment using Channa striatus. Several studies have been carried out to examine 
the efficacy and contents of Channa striatus meat. Indeed, the Channa striatus did 
contain all the essential amino acids and fatty acids uniquely capable of accelerating 
the wound healing. Early in January 2003, Eddy Suprayitno from Indonesia studied 
about Channa striatus extract for wound healing. The study was conducted by using 
Channa striatus extract as a substitute for serum albumin which is normally used for 
surgical wound healing. Channa striatus extract was prepared by steaming the 
cleaned Channa striatus fish and water extract. The water extract was drunk 
immediately to new patients after surgery. The results of Suprayitno study showed 
that the wounds of patients treated with Channa striatus extract healed within three 
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days faster than the wounds of patients which treated with serum albumin 
(Yellowfin, 2004). 
Channa striatus, a fresh water fish indigenous to many tropical countries 
have long been regarded as valuable food fish in the Far East. Their flesh is claimed 
to be rejuvenating, particularly in recuperation from serious illness and in a post-
natal diet. It is consumed for its putative effects on wound healing (Mat Jais, 2007; 
Mat Jais et al., 1994). It is also used by the patients in the post-operative period in the 
belief that it promotes wound healing and reduces post operative pain and 
discomfort. This fish is known to contain polyunsaturated fatty acids that can 
regulate prostaglandin synthesis and hence induce wound healing (Turek, 2007). 
Certain amino acids like glycine, aspartic and glutamic acid are also known to play 
important roles in the process of wound healing (Ahuja et al., 2007; Dylewski and 
Yu, 2007; Schoemann et al., 2007). Despite the wide-spread uses of this fish for 
medicinal purposes, there have been hardly any studies to establish the scientific 
basis for its claimed wound healing effects. Previously (Mat Jais et al., 1994) 
reported that the fatty acid composition of Channa striatus may account for the 
promotion of wound healing process. Gam et al. (2005) reported that there are no 
significant differences in the content of amino acid and fatty acid compositions in 
this snakehead fish of various sizes and obtained at different times of the year 
(Courtenay et al., 2007). Cream extracts of Channa striatus tissues contain high 
levels of arachidonic acid, a precursor of prostaglandin, essential amino acids 
(particularly glycine) and polyunsaturated fatty acids necessary to promote 
prostaglandin synthesis. Treating wounds with these extracts has been demonstrated 
to promote synthesis of collagen fibers better than standard use of Cetrimide, an 
antimicrobial quaternary ammonium compound. In that study, Channa striatus 
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extract was shown to increase the tensile strength of the surgically stitched wounds 
when compared to those treated with Cetrimide cream (Baie and Sheikh, 2000a). 
 
1.3.1 Amino acids in Channa striatus 
Amino acids are molecules containing an amine group, a carboxylic acid 
group and a side chain that vary between different amino acids. These molecules 
contain the key elements of carbon, hydrogen, oxygen, and nitrogen. These 
molecules are particularly important in biochemistry and referred to as alpha-amino 
acids with the general formula H2NCHRCOOH, where R is an organic substituent. In 
an alpha amino acid, the amino and carboxylate groups are attached to the same 
carbon atom, which is called the α-carbon. The various alpha amino acids differ in 
the side chain (R group) which is attached to their alpha carbon. These R groups can 
vary in size from just a hydrogen atom in glycine, to a methyl group in alanine, 
through to a large heterocyclic group in tryptophan (Banga, 2006; Womack and 
Rose, 1947).  
Amino acids are critical to life and have many functions in metabolism. One 
particularly important function is as the building blocks of proteins, which are linear 
chains of amino acids. Every protein is chemically defined by this primary structure, 
its unique sequence of amino acid residues, which in turn define the three-
dimensional structure of the protein ("The Structures of Life," 2008). Amino acids 
are also important in many other biological molecules, such as forming parts 
of coenzymes, as in S-adenosylmethionine, or as precursors for the biosynthesis of 
molecules such as heme (Womack and Rose, 1947). 
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Table 1.8: Structure of 20 L-α-amino acids found in proteins (Woodbury, 2006; 
Thornton and Barlow, 1991) 
 
No. Amino acid Three- and one- 
letter codes 
Side chain/structure 
1 
2 
3 
4 
5 
6 
7 
8 
 
9 
 
 
 
 
10 
11 
12 
13 
 
14 
 
 
 
 
 
 
15 
 
 
 
16 
17 
 
18 
 
 
 
19 
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Alanine 
Arginine 
Asparagine
f
 
Aspartic acid
f
 
Cysteine 
Glutamic acid
f
 
Glutamine
f
 
Glycine 
 
Histidine 
 
 
 
 
Isoleucine 
Leucine 
Lysine 
Methionine 
 
Phenylalanine 
 
 
 
 
 
 
Proline
g
 
 
 
 
Serine 
Threonine 
 
Tryptophan 
 
 
 
Tyrosine 
 
 
 
 
 
Valine 
ALA (A) 
ARG (R) 
ASN (N) 
ASP (D) 
CYS (C) 
GLU (E) 
GLN (Q) 
GLY (G) 
 
HIS (H) 
 
 
 
 
ILE (I) 
LEU (L) 
LYS (K) 
MET (M) 
 
PHE (F) 
 
 
 
 
 
 
PRO (P) 
 
 
 
SER (S) 
THR (T) 
 
TRP (W) 
 
 
 
TYR (Y) 
 
 
 
 
 
VAL (V) 
-CH3 
-(CH2)3-NH-C-(NH)NH2 
-CH2-CONH2 
-CH2-COOH 
-CH2-SH 
-(CH2)2-COOH 
-(CH2)2-CONH2 
-H 
 
 
 
-CH(CH3)CH2CH3 
-CH2-CH(CH3)2 
-(CH2)4-NH2 
-(CH2)2-S-CH3 
 
 
 
 
-CH2-OH 
-CH(CH3)OH 
 
 
 
-CH-(CH3)2 
